+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nocturia Market - Global Forecast 2026-2032- Product Image
Nocturia Market - Global Forecast 2026-2032- Product Image
Sale

Nocturia Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6117438
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Nocturia Market is projected to reach USD 3.48 Billion in 2026. It is expected to continue growing at a CAGR of 10.28%, reaching USD 6.25 Billion by 2032.

Nocturia: A Clinically Significant Symptom With Broad Health-System Implications

Nocturia-the need to wake during the night to urinate-is a symptom rather than a single disease. It can arise from nocturnal polyuria, reduced bladder storage, sleep disorders, medication effects, or conditions such as diabetes, heart failure, kidney disease, and urinary tract disorders. Its impact extends beyond disrupted sleep to daytime fatigue, impaired concentration, falls, mood changes, and reduced quality of life. Effective management therefore depends on identifying underlying causes and tailoring care to the individual rather than treating nighttime urination in isolation.

Integrated Assessment Is Replacing Single-Symptom Management

Care is shifting toward structured assessment of voiding patterns, fluid intake, sleep quality, medications, mobility, and comorbidities. Bladder diaries and validated symptom questionnaires can help distinguish nocturnal polyuria from diminished bladder capacity and sleep-related awakenings. Clinicians are also placing greater emphasis on medication review, evening fluid and caffeine habits, leg edema, glycemic control, and sleep-disordered breathing. This integrated approach supports safer treatment selection, particularly for older adults who may face elevated risks from falls, electrolyte disturbances, and polypharmacy.

Artificial Intelligence Can Strengthen Triage, Pattern Recognition, and Follow-Up

Artificial intelligence can support nocturia care by analyzing bladder-diary entries, wearable sleep signals, medication records, and longitudinal clinical data to identify patterns that may warrant evaluation. Predictive tools could help distinguish likely nocturnal polyuria, sleep fragmentation, or worsening comorbidity, while conversational interfaces may improve symptom tracking and adherence. However, these applications require clinically representative data, transparent validation, privacy safeguards, and human oversight. AI should augment diagnostic reasoning and monitoring, not replace assessment of red-flag symptoms or individualized clinical judgment.

Regional Differences Reflect Aging, Comorbidity, Access, and Care Pathways

In North America, primary-care screening, specialist referral, and digital monitoring are supported by established health infrastructure, although fragmented care and affordability can impede continuity. Latin America faces uneven access to urology, continence services, diagnostics, and medicines, making practical behavioral guidance and primary-care training important. Europe benefits from mature clinical guidance and aging-population research, while national differences in reimbursement and service organization shape access. In the Middle East, rapid urbanization, diabetes prevalence, and variable specialist capacity influence detection and treatment. Africa requires approaches adapted to constrained diagnostic resources, infectious and chronic disease burdens, and substantial urban-rural variation. Asia-Pacific combines advanced specialist services in some economies with large underserved populations elsewhere, creating demand for scalable primary-care pathways and culturally appropriate education.

Economic and Policy Groupings Reveal Shared but Uneven Priorities

Across ASEAN, diverse health-system capacity and urban-rural access make standardized symptom assessment and workforce education valuable. BRICS countries share significant population diversity and chronic-disease burdens but differ widely in reimbursement, digital infrastructure, and specialist availability. The European Union can benefit from harmonized clinical data practices, aging-related policy coordination, and cross-border learning, while national implementation remains important. G7 systems generally have strong research and digital capabilities but must address aging, multimorbidity, workforce pressure, and equitable access. GCC countries can leverage concentrated health infrastructure and digital investment while adapting services to population mobility and chronic disease patterns. Within NATO, collaboration in health resilience, interoperability, and clinical research may support nocturia management, although civilian care remains shaped by national systems.

Country Contexts Shape Screening, Referral, and Treatment Delivery

In Australia, dispersed populations make telehealth and primary-care protocols useful complements to specialist services. Brazil and Mexico require scalable pathways that address regional disparities and strengthen first-contact assessment. Canada faces geographic access challenges alongside an aging population and the need for coordinated chronic-care management. China and India have substantial variation between metropolitan and rural services, supporting tiered models that combine specialist expertise with trained primary care. France, Germany, Italy, and Spain operate within established European clinical environments but differ in referral, reimbursement, and care coordination. Japan and South Korea must address nocturia in the context of advanced population aging and high technology adoption. In the United Kingdom, integrated care and primary-care triage can support systematic evaluation. In the United States, fragmented delivery, insurance variation, and medication burden make coordinated assessment and patient education particularly important. Russia requires attention to regional service variation, chronic disease management, and access to specialist evaluation.

Industry Leaders Should Prioritize Safe, Integrated, and Measurable Care Models

Leaders should develop solutions around cause-based assessment rather than symptom suppression alone. Priorities include validated bladder-diary workflows, medication and comorbidity review, fall-risk screening, and clear escalation criteria for hematuria, dysuria, edema, excessive thirst, or acute change. Digital tools should be interoperable with clinical records, accessible to older adults, and designed for low-connectivity settings where needed. Evidence generation should measure sleep quality, daytime function, falls, adherence, and patient-reported outcomes-not only episode frequency. Partnerships with primary care, urology, geriatrics, sleep medicine, pharmacies, and patient organizations can improve adoption while supporting responsible AI governance and equitable access.

Methodology: Evidence Synthesis Anchored in Clinical and Health-System Context

This executive summary is based on an evidence-oriented review framework for nocturia that integrates clinical definitions, recognized contributing conditions, diagnostic principles, treatment considerations, demographic factors, and health-system variation. The analysis distinguishes nocturia from related conditions such as overactive bladder, enuresis, and sleep fragmentation, and emphasizes findings that are broadly supported by clinical practice and population-health research. Regional, group, and country observations are presented as contextual interpretations rather than numerical market claims. No market estimates, shares, forecasts, or company-specific assessments are included.

Better Nocturia Outcomes Depend on Addressing the Whole Patient

Nocturia is best understood as a multifactorial symptom with consequences for sleep, safety, functioning, and chronic-disease management. The strongest pathway forward combines systematic assessment, targeted treatment of underlying causes, practical self-management support, and coordinated follow-up. Regional and country differences make adaptable delivery essential, while AI can improve pattern recognition and monitoring when validated and governed responsibly. Industry and health-system leaders that focus on clinical usefulness, patient safety, interoperability, and equitable access will be better positioned to improve outcomes for people affected by nocturnal urination.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Nocturia Market, by Treatment Type
7.1. Introduction
7.2. Non Pharmacological
7.2.1. Behavioral Therapy
7.2.2. Electrostimulation
7.2.3. Fluid Restriction
7.3. Pharmacological
7.3.1. Anticholinergics
7.3.2. Desmopressin
7.3.3. Diuretics
8. Nocturia Market, by Etiology
8.1. Introduction
8.2. Nocturnal Polyuria
8.3. Reduced Bladder Capacity
8.4. Sleep Disorders
9. Nocturia Market, by Gender
9.1. Introduction
9.2. Female
9.3. Male
10. Nocturia Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Clinics
10.4. Home Care
10.5. Hospitals
11. Nocturia Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Nocturia Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Nocturia Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Nocturia Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AA Pharma Inc.
16.2. Astellas Pharma Inc.
16.3. Avadel Pharmaceuticals plc
16.4. Bayer AG
16.5. Boehringer Ingelheim International GmbH
16.6. Dr. Reddy's Laboratories Limited
16.7. Eisai Co., Ltd.
16.8. Eli Lilly and Company
16.9. Endo International plc
16.10. Ferring Pharmaceuticals
16.11. Glenmark Pharmaceuticals Limited
16.12. Ipsen S.A.
16.13. Mylan N.V.
16.14. Novartis International AG
16.15. Otsuka Pharmaceutical Co., Ltd.
16.16. Pfizer Inc.
16.17. Recordati S.p.A.
16.18. Sanofi S.A.
16.19. Serenity Pharmaceuticals LLC
16.20. Sumitomo Pharma Co., Ltd.
16.21. Sun Pharmaceutical Industries Ltd.
16.22. Takeda Pharmaceutical Company Limited
16.23. Teva Pharmaceutical Industries Ltd.
16.24. UroGen Pharma Ltd.
16.25. Urovant Sciences Inc.
16.26. Vantia Therapeutics Inc.
16.27. Viatris Inc.
16.28. Wellesley Pharmaceuticals Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Nocturia Market, Years Considered for the Study
FIGURE 2. Global Nocturia Market, Research Design
FIGURE 3. Global Nocturia Market, Research Framework
FIGURE 4. Global Nocturia Market, Data Triangulation
FIGURE 5. Global Nocturia Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Nocturia Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 7. Global Nocturia Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Nocturia Market Size, by Etiology, 2025 vs 2032 (%)
FIGURE 9. Global Nocturia Market Size, by Etiology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Nocturia Market Size, by Gender, 2025 vs 2032 (%)
FIGURE 11. Global Nocturia Market Size, by Gender, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Nocturia Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Nocturia Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Nocturia Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Nocturia Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Nocturia Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Nocturia Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Nocturia Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Nocturia Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Nocturia Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Nocturia Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Nocturia Market Segmentation & Coverage
TABLE 2. Global Nocturia Market Size, 2017-2032 (USD Million)
TABLE 3. Global Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 4. Global Non Pharmacological Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Non Pharmacological Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Non Pharmacological Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Behavioral Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Behavioral Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Behavioral Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Electrostimulation Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Electrostimulation Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Electrostimulation Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Fluid Restriction Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Fluid Restriction Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Fluid Restriction Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Pharmacological Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Pharmacological Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Pharmacological Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Anticholinergics Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Anticholinergics Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Anticholinergics Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Desmopressin Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Desmopressin Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Desmopressin Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Diuretics Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Diuretics Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Diuretics Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 29. Global Nocturnal Polyuria Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Nocturnal Polyuria Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Nocturnal Polyuria Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Reduced Bladder Capacity Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Reduced Bladder Capacity Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Reduced Bladder Capacity Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Sleep Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Sleep Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Sleep Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 39. Global Female Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Female Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Female Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Male Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Male Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Male Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 46. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 59. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Nocturia Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Nocturia Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. North America Nocturia Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. North America Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 79. North America Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 80. North America Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 81. North America Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 82. North America Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 83. North America Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 84. North America Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 85. Latin America Nocturia Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Latin America Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 87. Latin America Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 88. Latin America Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 89. Latin America Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 90. Latin America Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 91. Latin America Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. Latin America Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. Europe Nocturia Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Europe Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 95. Europe Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 96. Europe Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 97. Europe Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 98. Europe Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 99. Europe Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 100. Europe Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 101. Middle East Nocturia Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Middle East Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 103. Middle East Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 104. Middle East Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 105. Middle East Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 106. Middle East Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 107. Middle East Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. Middle East Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. Africa Nocturia Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Africa Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 111. Africa Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 112. Africa Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 113. Africa Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 114. Africa Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 115. Africa Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. Africa Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Global Nocturia Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. ASEAN Nocturia Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. ASEAN Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 120. ASEAN Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 121. ASEAN Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 122. ASEAN Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 123. ASEAN Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 124. ASEAN Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. ASEAN Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. GCC Nocturia Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. GCC Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 128. GCC Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 129. GCC Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 130. GCC Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 131. GCC Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 132. GCC Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. GCC Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. European Union Nocturia Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. European Union Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 136. European Union Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 137. European Union Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 138. European Union Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 139. European Union Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 140. European Union Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. European Union Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 142. BRICS Nocturia Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. BRICS Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 144. BRICS Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 145. BRICS Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 146. BRICS Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 147. BRICS Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 148. BRICS Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 149. BRICS Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. G7 Nocturia Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. G7 Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 152. G7 Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 153. G7 Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 154. G7 Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 155. G7 Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 156. G7 Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. G7 Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. NATO Nocturia Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. NATO Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 160. NATO Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 161. NATO Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 162. NATO Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 163. NATO Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 164. NATO Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. NATO Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. Global Nocturia Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. United States Nocturia Market Size, 2017-2032 (USD Million)
TABLE 168. United States Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 169. United States Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 170. United States Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 171. United States Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 172. United States Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 173. United States Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. United States Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. Canada Nocturia Market Size, 2017-2032 (USD Million)
TABLE 176. Canada Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 177. Canada Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 178. Canada Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 179. Canada Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 180. Canada Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 181. Canada Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. Canada Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. Mexico Nocturia Market Size, 2017-2032 (USD Million)
TABLE 184. Mexico Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 185. Mexico Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 186. Mexico Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 187. Mexico Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 188. Mexico Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 189. Mexico Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Mexico Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. Brazil Nocturia Market Size, 2017-2032 (USD Million)
TABLE 192. Brazil Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 193. Brazil Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 194. Brazil Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 195. Brazil Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 196. Brazil Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 197. Brazil Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 198. Brazil Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. United Kingdom Nocturia Market Size, 2017-2032 (USD Million)
TABLE 200. United Kingdom Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 201. United Kingdom Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 202. United Kingdom Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 203. United Kingdom Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 204. United Kingdom Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 205. United Kingdom Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 206. United Kingdom Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. Germany Nocturia Market Size, 2017-2032 (USD Million)
TABLE 208. Germany Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 209. Germany Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 210. Germany Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 211. Germany Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 212. Germany Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 213. Germany Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. Germany Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. France Nocturia Market Size, 2017-2032 (USD Million)
TABLE 216. France Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 217. France Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 218. France Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 219. France Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 220. France Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 221. France Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. France Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. Russia Nocturia Market Size, 2017-2032 (USD Million)
TABLE 224. Russia Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 225. Russia Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 226. Russia Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 227. Russia Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 228. Russia Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 229. Russia Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. Russia Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 231. Italy Nocturia Market Size, 2017-2032 (USD Million)
TABLE 232. Italy Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 233. Italy Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 234. Italy Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 235. Italy Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 236. Italy Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 237. Italy Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 238. Italy Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. Spain Nocturia Market Size, 2017-2032 (USD Million)
TABLE 240. Spain Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 241. Spain Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 242. Spain Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 243. Spain Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 244. Spain Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 245. Spain Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 246. Spain Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. China Nocturia Market Size, 2017-2032 (USD Million)
TABLE 248. China Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 249. China Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 250. China Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 251. China Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 252. China Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 253. China Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. China Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. India Nocturia Market Size, 2017-2032 (USD Million)
TABLE 256. India Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 257. India Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 258. India Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 259. India Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 260. India Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 261. India Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 262. India Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Japan Nocturia Market Size, 2017-2032 (USD Million)
TABLE 264. Japan Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 265. Japan Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 266. Japan Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 267. Japan Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 268. Japan Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 269. Japan Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 270. Japan Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 271. Australia Nocturia Market Size, 2017-2032 (USD Million)
TABLE 272. Australia Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 273. Australia Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 274. Australia Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 275. Australia Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 276. Australia Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 277. Australia Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 278. Australia Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 279. South Korea Nocturia Market Size, 2017-2032 (USD Million)
TABLE 280. South Korea Nocturia Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 281. South Korea Nocturia Market Size, by Non Pharmacological, 2017-2032 (USD Million)
TABLE 282. South Korea Nocturia Market Size, by Pharmacological, 2017-2032 (USD Million)
TABLE 283. South Korea Nocturia Market Size, by Etiology, 2017-2032 (USD Million)
TABLE 284. South Korea Nocturia Market Size, by Gender, 2017-2032 (USD Million)
TABLE 285. South Korea Nocturia Market Size, by End User, 2017-2032 (USD Million)
TABLE 286. South Korea Nocturia Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 287. Global Nocturia Market Share, by Key Player, 2025
TABLE 288. Global Nocturia Market, Key Experts

Companies Mentioned

  • AA Pharma Inc.
  • Astellas Pharma Inc.
  • Avadel Pharmaceuticals plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Ferring Pharmaceuticals
  • Glenmark Pharmaceuticals Limited
  • Ipsen S.A.
  • Mylan N.V.
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Recordati S.p.A.
  • Sanofi S.A.
  • Serenity Pharmaceuticals LLC
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UroGen Pharma Ltd.
  • Urovant Sciences Inc.
  • Vantia Therapeutics Inc.
  • Viatris Inc.
  • Wellesley Pharmaceuticals Inc.

Related Topics

Related Reports

Nocturia Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035 - Product Image

Nocturia Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035

  • Report
  • Global
From
Nocturia Market Report 2026 - Product Image

Nocturia Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Updates in Geriatric Urology, An Issue of Clinics in Geriatric Medicine. The Clinics: Internal Medicine Volume 41-2 - Product Image

Updates in Geriatric Urology, An Issue of Clinics in Geriatric Medicine. The Clinics: Internal Medicine Volume 41-2

  • Book
Current Medical and Surgical Treatments for Benign Prostatic Hyperplasia, An Issue of Urologic Clinics of North America. The Clinics: Surgery Volume 52-4 - Product Image

Current Medical and Surgical Treatments for Benign Prostatic Hyperplasia, An Issue of Urologic Clinics of North America. The Clinics: Surgery Volume 52-4

  • Book
  • North America
Urea Cycle Disorder Agent Market - Global Forecast 2026-2032 - Product Image

Urea Cycle Disorder Agent Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.